4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
申请人:——
公开号:US20020187978A1
公开(公告)日:2002-12-12
The present invention relates to certain 4-heteroaryl-3-heteroarylidenyl-2-indolinones compounds and their physiologically acceptable salts which modulate the activity of protein kinases (“PKs”), in particular CDK2. The compounds of the present invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical composition containing these compounds and methods of preparing these compounds are also described.
4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
申请人:Sugen, Inc.
公开号:US20040097497A1
公开(公告)日:2004-05-20
The present invention relates to certain 4-heteroaryl-3-heteroarylidenyl-2-indolinones compounds and their physiologically acceptable salts which modulate the activity of protein kinases (“PKs”), in particular CDK2. The compounds of the present invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical composition containing these compounds and methods of preparing these compounds are also described.
Bi-functional complexes and methods for making and using such complexes
申请人:Gouliaev Alex Haahr
公开号:US11225655B2
公开(公告)日:2022-01-18
The present invention is directed to a method for the synthesis of a bi-functional complex comprising a molecule part and an identifier oligonucleotide part identifying the molecule part. A part of the synthesis method according to the present invention is preferably conducted in one or more organic solvents when a nascent bi-functional complex comprising an optionally protected tag or oligonucleotide identifier is linked to a solid support, and another part of the synthesis method is preferably conducted under conditions suitable for enzymatic addition of an oligonucleotide tag to a nascent bi-functional complex in solution.